![]() |
![]() |
My Amedeo
![]() ![]() ![]() |
![]() |
|||||||||
The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al. |
Bladder Cancer |
Free Subscription
1 Am J Clin Pathol |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Bladder Cancer is free of charge.
Comparative evaluation of PD-L1 expression and tumor immune microenvironment in
molecular subtypes of muscle-invasive bladder cancer and its correlation with
survival outcomes.
Am J Clin Pathol. 2025 Jan 13:aqae176. doi: 10.1093.
PubMed
Abstract available
Circ-ITCH inhibits bladder cancer progression through miR-184/FOXO3 axis.
Am J Transl Res. 2024;16:7911-7923.
PubMed
Abstract available
Differential Diagnosis of Urinary Cancers by Surface-Enhanced Raman Spectroscopy
and Machine Learning.
Anal Chem. 2025;97:27-32.
PubMed
Abstract available
Circ-NMNAT1 Drives Tumor Progression in Bladder Cancer by Modulating the
miR-370-3p/ATXN2L Axis.
Appl Biochem Biotechnol. 2025 Jan 16. doi: 10.1007/s12010-024-05162.
PubMed
Abstract available
Robotic Laparoscopy and Endoscopy Cooperative Surgery for Primary Appendiceal
Mucinous Carcinoma Masquerading as Bladder Cancer: A Case Report.
Asian J Endosc Surg. 2025;18:e70021.
PubMed
Abstract available
Matrix Metalloproteinase-9 is associated with tumor microenvironment remodeling
of bladder cancer.
Biol Direct. 2025;20:8.
PubMed
Abstract available
Spatial distribution and subtype-specific expression patterns of Nectin-4 in
muscle-invasive bladder cancer.
BJU Int. 2025 Jan 13. doi: 10.1111/bju.16643.
PubMed
Abstract available
Tattoos as a risk factor for bladder cancer: a call for cohort studies.
BJU Int. 2025 Jan 14. doi: 10.1111/bju.16648.
PubMed
Neuroendocrine tumour of the urinary bladder.
BMJ Case Rep. 2025;18:e263265.
PubMed
Abstract available
PIN1 prolyl isomerase promotes initiation and progression of bladder cancer
through the SREBP2-mediated cholesterol biosynthesis pathway.
Cancer Discov. 2025 Jan 14. doi: 10.1158/2159-8290.CD-24-0866.
PubMed
Abstract available
Comprehensive Genetic Profile of Chinese Muscle-Invasive Bladder Cancer Cohort.
Clin Genitourin Cancer. 2024;23:102280.
PubMed
Abstract available
Feasibility and Oncological Outcome of Patients Achieving Noninvasive Downstaging
After Transurethral Resection of Bladder Tumor Plus Systemic Chemotherapy for
Bladder Preservation Strategy in Muscle-Invasive Bladder Cancer.
Clin Genitourin Cancer. 2024;23:102290.
PubMed
Abstract available
Is there a role for neoadjuvant therapies followed by radical cystectomy in
oligometastatic bladder cancer?
Curr Opin Urol. 2025 Jan 17. doi: 10.1097/MOU.0000000000001261.
PubMed
Abstract available
Membrane palmitoylated protein MPP1 inhibits immune escape by regulating the
USP12/ CCL5 axis in urothelial carcinoma.
Int Immunopharmacol. 2025;146:113802.
PubMed
Abstract available
The MCM6-c-Myc positive feedback loop mediates bladder cancer progression and
cisplatin resistance.
Int J Biol Macromol. 2025;296:139777.
PubMed
Abstract available
Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral
Resection for Staging New Bladder Cancers: Results From the Prospective
BladderPath Trial.
J Clin Oncol. 2025 Jan 14:JCO2302398. doi: 10.1200/JCO.23.02398.
PubMed
Abstract available
The incidence and risk factor for febrile urinary tract infection after
robot-assisted laparoscopic radical cystectomy in bladder cancer patients.
J Infect Chemother. 2025 Jan 15:102624. doi: 10.1016/j.jiac.2025.102624.
PubMed
Abstract available
Immunohistochemistry-based molecular subtypes of urothelial carcinoma derive
different survival benefit from platinum chemotherapy.
J Pathol Clin Res. 2025;11:e70017.
PubMed
Abstract available
SRT3025-loaded cell membrane hybrid liposomes (3025@ML) enhanced anti-tumor
activity of Oxaliplatin via inhibiting pyruvate kinase M2 and fatty acid
synthase.
Lipids Health Dis. 2025;24:14.
PubMed
Abstract available
Diagnostic accuracy of urinary cytokeratin fragment-19 (CYFRA21-1) for bladder
cancer.
Narra J. 2024;4:e1142.
PubMed
Abstract available
Long non-coding RNAs as prognostic biomarkers in non-muscle invasive bladder
cancer: A systematic review.
Narra J. 2024;4:e1233.
PubMed
Abstract available
Loss of Kmt2c or Kmt2d primes urothelium for tumorigenesis and redistributes
KMT2A-menin to bivalent promoters.
Nat Genet. 2025;57:165-179.
PubMed
Abstract available
Experience and Prognostic Analysis with Avelumab Switch Maintenance Treatment in
Metastatic Urothelial Carcinoma.
Oncology. 2025;103:11-21.
PubMed
Abstract available
Upper Extremity Mass as First Presentation of Metastatic Urothelial Carcinoma.
Orthopedics. 2025;48:e52-e55.
PubMed
Abstract available
Non-coding RNAs in urinary bladder cancer microenvironment: Diagnostic,
therapeutic, and prognostic perspective.
Pathol Res Pract. 2025;266:155815.
PubMed
Abstract available
Research progress of near-infrared fluorescence imaging in accurate theranostics
in bladder cancer.
Photodiagnosis Photodyn Ther. 2025 Jan 9:104480.
PubMed
Abstract available
Non-thermal plasma as promising anti-cancer therapy against bladder cancer by
inducing DNA damage and cell cycle arrest.
Sci Rep. 2025;15:2334.
PubMed
Abstract available
Unveiling urinary extracellular vesicle mRNA signature for early diagnosis and
prognosis of bladder cancer.
Theranostics. 2025;15:1272-1284.
PubMed
Abstract available
Construction of a disulfidptosis-associated lncRNA signature to predict prognosis
in bladder cancer.
Transl Androl Urol. 2024;13:2705-2723.
PubMed
Abstract available
Validation of clinical T stages and of prognostic negative markers in patients
with muscle invasive bladder cancer: data in the Swedish National Bladder Cancer
Registry vs. data from a detailed research database.
Transl Androl Urol. 2024;13:2757-2770.
PubMed
Abstract available
Molecular profiling of bladder cancer xenografts defines relevant molecular
subtypes and provides a resource for biomarker discovery.
Transl Oncol. 2025;52:102269.
PubMed
Abstract available
Study of urine-based mRNA biomarkers for early detection of nonmuscle invasive
bladder cancer (NMIBC).
Urol Oncol. 2025 Jan 11:S1078-1439(24)01050.
PubMed
Abstract available
Development of TAR-200: A novel targeted releasing system designed to provide
sustained delivery of gemcitabine for patients with bladder cancer.
Urol Oncol. 2025 Jan 15:S1078-1439(24)01044.
PubMed
Abstract available
[Enfortumab vedotin and pembrolizumab : Management of side effects during first
line combined treatment for advanced or metastatic urothelial carcinoma].
Urologie. 2025;64:60-74.
PubMed
Abstract available
A comparison between intravesical gemcitabine plus docetaxel and intravesical BCG
in the treatment of non-muscle invasive naive urinary bladder cancer: A
systematic review and meta-analysis of oncological outcomes.
Urology. 2025 Jan 9:S0090-4295(25)00006-8. doi: 10.1016/j.urology.2025.
PubMed
Abstract available
Clinical outcome of BCG treatment for patients with urothelial carcinoma of the
prostatic urethra: Implications for early cystectomy.
World J Urol. 2025;43:71.
PubMed
Abstract available
A multicenter study of perioperative and functional outcomes of open vs. robot
assisted uretero-enteric reimplantation after radical cystectomy.
World J Urol. 2025;43:74.
PubMed
Abstract available
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
[Impacts of curcumin on proliferation, migration and cisplatin resistance of
bladder cancer cells by regulating LKB1-AMPK-LC3 signaling pathway].
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2025;41:9-16.
PubMed
Abstract available
Thank you for your interest in scientific medicine.